Fully Automatic Deep Learning Pipeline for Whole Slide Image Quality Assessment

📅 2024-11-25
🏛️ arXiv.org
📈 Citations: 0
Influential: 0
📄 PDF

career value

180K/year
🤖 AI Summary
Artifacts (e.g., folds, blur, background regions) in whole-slide images (WSIs) degrade the performance of downstream deep learning models in computational pathology. Method: We propose an end-to-end WSI quality assessment and artifact region removal framework. Our approach integrates CNN and Vision Transformer (ViT) modules into a pixel-level semantic segmentation architecture, enabling unsupervised preprocessing-free quality grading. The model is trained on a large-scale, multi-source WSI dataset encompassing diverse organs, scanners, and staining protocols. Contribution/Results: Extensive internal and external multi-center validation demonstrates superior generalizability: artifact detection achieves >95% accuracy, precision, recall, and F1-score—significantly outperforming current state-of-the-art methods. By automatically identifying and excluding artifact-contaminated regions, our method substantially enhances the reliability and robustness of training data for computational pathology models.

Technology Category

Application Category

📝 Abstract
In recent years, the use of deep learning (DL) methods, including convolutional neural networks (CNNs) and vision transformers (ViTs), has significantly advanced computational pathology, enhancing both diagnostic accuracy and efficiency. Hematoxylin and Eosin (H&E) Whole Slide Images (WSI) plays a crucial role by providing detailed tissue samples for the analysis and training of DL models. However, WSIs often contain regions with artifacts such as tissue folds, blurring, as well as non-tissue regions (background), which can negatively impact DL model performance. These artifacts are diagnostically irrelevant and can lead to inaccurate results. This paper proposes a fully automatic supervised DL pipeline for WSI Quality Assessment (WSI-QA) that uses a fused model combining CNNs and ViTs to detect and exclude WSI regions with artifacts, ensuring that only qualified WSI regions are used to build DL-based computational pathology applications. The proposed pipeline employs a pixel-based segmentation model to classify WSI regions as either qualified or non-qualified based on the presence of artifacts. The proposed model was trained on a large and diverse dataset and validated with internal and external data from various human organs, scanners, and H&E staining procedures. Quantitative and qualitative evaluations demonstrate the superiority of the proposed model, which outperforms state-of-the-art methods in WSI artifact detection. The proposed model consistently achieved over 95% accuracy, precision, recall, and F1 score across all artifact types. Furthermore, the WSI-QA pipeline shows strong generalization across different tissue types and scanning conditions.
Problem

Research questions and friction points this paper is trying to address.

Detects artifacts in Whole Slide Images
Improves DL model accuracy in pathology
Ensures only qualified WSI regions used
Innovation

Methods, ideas, or system contributions that make the work stand out.

Fused CNNs and ViTs model
Pixel-based segmentation for WSI
Automated artifact detection pipeline
F
Falah Jabar
Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway
Lill-Tove Rasmussen Busund
Lill-Tove Rasmussen Busund
Professor i patologi, UiT
forskning
B
Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
Masoud Tafavvoghi
Masoud Tafavvoghi
UiT The Arctic University of Norway
computational pathologymachine learningdeep learningmedical imaging
Mette Pøhl
Mette Pøhl
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
S
Sigve Andersen
Department of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway; Department of Oncology, University Hospital of North Norway, Tromso, Norway
T
Tom Donnem
Department of Clinical Medicine, UiT The Arctic University of Norway, Tromso, Norway; Department of Oncology, University Hospital of North Norway, Tromso, Norway
D
David J. Kwiatkowski
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
Mehrdad Rakaee
Mehrdad Rakaee
Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway; Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway